Arcus Biosciences, Inc. Deferred Revenue Recognized
Arcus Biosciences, Inc. (RCUS) reported Deferred Revenue Recognized of $35.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-05
- Arcus Biosciences, Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-06-30 was $35.00M, a 78.13% decline year-over-year.
- Arcus Biosciences, Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $17.00M, a 39.29% decline year-over-year.
- Arcus Biosciences, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-09-30 was $26.00M, a 21.21% decline year-over-year.
- Arcus Biosciences, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-06-30 was $160.00M, a 310.26% increase year-over-year.
- Arcus Biosciences, Inc. contract with customer, liability, revenue recognized for fiscal 2025 was $240.00M, a 1.23% decline from fiscal 2024.
- Arcus Biosciences, Inc. contract with customer, liability, revenue recognized for fiscal 2024 was $243.00M, a 125.00% increase from fiscal 2023.
- Arcus Biosciences, Inc. contract with customer, liability, revenue recognized for fiscal 2023 was $108.00M, a 3.57% decline from fiscal 2022.
- Arcus Biosciences, Inc. contract with customer, liability, revenue recognized for fiscal 2022 was $112.00M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $35.00M 10-Q · filed 2026-08-05 | $52.00M 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | $17.00M 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | $240.00M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $26.00M 10-Q · filed 2025-10-28 | $214.00M 10-Q · filed 2025-10-28 | ||
| 2025-06-30 | $160.00M 10-Q · filed 2026-08-05 | $188.00M 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | $28.00M 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | $243.00M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $33.00M 10-Q · filed 2025-10-28 | $212.00M 10-Q · filed 2025-10-28 | ||
| 2024-06-30 | $39.00M 10-Q · filed 2025-08-06 | $180.00M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $142.00M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $108.00M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $28.00M 10-Q · filed 2024-11-06 | $79.00M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $28.00M 10-Q · filed 2024-08-08 | $53.00M 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $112.00M 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |